POLR2A and neoplasm: Recognizing this functional overlap between viral infection and tumor biology opens new therapeutic opportunities: oncolytic viruses and transcription-targeted agents may be strategically leveraged to disrupt tumor-specific vulnerabilities driven by the POLR2A/RPB1 axis.